Semaglutide Dosage: Reported Research Ranges
Reported in research: 0.25–2.4 mg once weekly (injection) and 3–14 mg once daily (oral tablet) in published human trials; practitioner protocols report 250 mcg–2.5 mg weekly. Sources vary.
Dosing Protocols Research · Peptide dosage chart · What is Semaglutide? · Research library
Reported ranges by source
| Reported range | Source type | Evidence strength |
|---|---|---|
| 0.25–2.4 mg once weekly, subcutaneous (lower starting amounts stepped up to 0.5, 1.0 or 2.4 mg) | Human trial (published study) | Human: randomized controlled trials |
| 3–14 mg once daily, oral form | Human trial (published study) | Human: randomized controlled trials |
| 250 mcg–2.5 mg once weekly; another source lists 2.4 mg weekly | Practitioner protocols | Practitioner protocol (not a clinical trial) |
Amounts are shown as each source reports them. Where sources disagree, the table lists each one; there is no single agreed amount.
Published human trials in our library
- Efficacy and safety of once-weekly semaglutide 2·[amount hidden] in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial · PubMed 42575111
- Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial · PubMed 42473259
- Short- and long-term effects of semaglutide [amount hidden] on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial · PubMed 42323166
- Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial · PubMed 42308057
- Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial · PubMed 42173109
- Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease · PubMed 42170981
- Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial · PubMed 42054055
- Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial · PubMed 41879791
- Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA) · PubMed 41527269
- Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial · PubMed 41419618
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 · PubMed 41328546
- Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial · PubMed 41144928
- Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial · PubMed 41066034
FAQ
What Semaglutide dosage is reported in research?
Reported in research: 0.25–2.4 mg once weekly (injection) and 3–14 mg once daily (oral tablet) in published human trials; practitioner protocols report 250 mcg–2.5 mg weekly. Sources vary.
Is there human-trial evidence for Semaglutide dosing?
Yes. Published randomized trials in our study library report the amounts in the table above.
Why do the reported Semaglutide amounts differ?
Each source studied or described a different group, form, goal and time frame, so reported amounts vary between sources. PeptideWhiz lists each one with its source type instead of picking a single amount.
Where can I convert a Semaglutide amount into syringe units?
The PeptideWhiz calculator for Semaglutide converts a vial amount, water volume and target amount into mL and syringe units. It does not suggest an amount.
Last updated: November 2, 2026.
Research information only. This page lists amounts as reported in published studies, practitioner protocols and Dr. Trevor reports. It is not medical advice and not a recommendation for any person. Sources vary, and most of these compounds are not approved for the uses discussed.